Sophie Stotz

Dr. Sophie Stotz

Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Hovedstaden, Denmark
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GBGregory Bowden
Gregory Bowden
Sophie StotzSophie Stotz
Sophie Stotz
JKJohannes Kinzler
Johannes Kinzler
CGChristian Geibel
Christian Geibel
MLMichael Lämmerhofer
Michael Lämmerhofer
AMAndreas Maurer
Andreas Maurer

6 September 2021 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
Sophie StotzSophie Stotz
Sophie Stotz
JKJohannes Kinzler
Johannes Kinzler
ANAnne Nies
Anne Nies
Matthias SchwabMatthias Schwab
Matthias Schwab
AMAndreas Maurer
Andreas Maurer
Purpose: Imaging of PARP expression has emerged as valuable strategy for prediction of tumor malignancy. While [18F]PARPi and [18F]FTT are already in clinical translation, both suffer from mainly hepatobiliary clearance hampering their use for detection of abdominal lesions, e.g., liver metastases. Our novel radiotracer [18F]FPyPARP aims to bridge this gap with a higher renal clearance and an easily translatable synthesis route for potential clinical application. Methods: We developed a less lipophilic variant of [18F]PARPi by exchange of the fluorobenzoyl residue with a fluoronicotinoyl group and automated the radiosyntheses of the three radiotracers. We then conducted a comparative side-by-side study of [18F]PARPi, [18F]FPyPARP, and [18F]FTT in NOD.CB17-Prkdcscid/J mice bearing HCC1937 xenografts to assess xenograft uptake and pharmacokinetics focusing on excretion pathways. Results: Together with decent uptake of all three radiotracers in the xenografts (tumor-to-blood ratios 3.41 ± 0.83, 3.99 ± 0.99, and 2.46 ± 0.35, respectively, for [18F]PARPi, [18F]FPyPARP, and [18F]FTT), a partial shift from hepatobiliary to renal clearance of [18F]FPyPARP was observed, whereas [18F]PARPi and [18F]FTT show almost exclusive hepatobiliary clearance. Conclusion: These findings imply that [18F]FPyPARP is an alternative to [18F]PARPi and [18F]FTT for PET imaging of PARP enzymes.

6 March 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
LZLatifa Zekri
Latifa Zekri
IHIlona Hagelstein
Ilona Hagelstein
MMMelanie Märklin
Melanie Märklin
BKBoris Klimovich
Boris Klimovich
MCMary Christie
Mary Christie
Helmut R. SalihHelmut R. Salih
Helmut R. Salih
Despite the advances in cancer treatment achieved, for example, by the CD20 antibody rituximab, an urgent medical need remains to optimize the capacity of such antibodies to induce antibody-dependent cellular cytotoxicity (ADCC) that determines therapeutic efficacy. The cytokine IL-15 stimulates proliferation, activation, and cytolytic capacity of NK cells, but broad clinical use is prevented by short half-life, poor accumulation at the tumor site, and severe toxicity due to unspecific immune activation. We here report modified immunocytokines consisting of Fc-optimized CD19 and CD20 antibodies fused to an IL-15 moiety comprising an L45E-E46K double mutation (MIC + format). The E46K mutation abrogated binding to IL-15Rα, thereby enabling substitution of physiological trans-presentation by target binding and thus conditional IL-15Rβγ stimulation, whereas the L45E mutation optimized IL-15Rβγ agonism and producibility. In vitro analysis of NK activation, anti-leukemia reactivity, and toxicity using autologous and allogeneic B cells confirmed target-dependent function of MIC + constructs. Compared with Fc-optimized CD19 and CD20 antibodies, MIC + constructs mediated superior target cell killing and NK cell proliferation. Mouse models using luciferase-expressing human NALM-6 lymphoma cells, patient acute lymphoblastic leukemia (ALL) cells, and murine EL-4 lymphoma cells transduced with human CD19/CD20 as targets and human and murine NK cells as effectors, respectively, confirmed superior and target-dependent anti-leukemic activity. In summary, MIC + constructs combine the benefits of Fc-optimized antibodies and IL-15 cytokine activity and mediate superior NK cell immunity with potentially reduced side effects. They thus constitute a promising new immunotherapeutic approach shown here for B cell malignancies.

3 September 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Sophie StotzSophie Stotz
Sophie Stotz
GBGregory Bowden
Gregory Bowden
JCJonathan Cotton
Jonathan Cotton
BPBernd J. Pichler
Bernd J. Pichler
AMAndreas Maurer
Andreas Maurer
There is a need for versatile in vivo nuclear imaging reporter systems to foster preclinical and clinical research. We explore the applicability of the SNAPTag and novel radiolabeled small-molecule ligands as a versatile reporter gene system for in vivo nuclear imaging. SNAPTag is a high-affinity protein tag used in a variety of biochemical research areas and based on the suicide DNA repair enzyme O6-methylguanine methyl transferase (MGMT). Its ligands are well suited for reporter gene imaging as the benzyl guanine core scaffold can be derivatized with fluorescent or radiolabeled moieties for various applications. Three guanine-based SNAPTag ligands ([18F]FBBG, [18F]pFBG and [18F]mFBG) were synthesized in high yields and were (radio)chemically characterized. HEK293 cells were engineered to express the SNAPTag on the cell surface and served as cell model to assess target affinity by radiotracer uptake assays, Western blotting and SDS-PAGE autoradiography. A subcutaneous HEK293-SNAPTag xenograft model in immunodeficient mice was used for in vivo evaluation of [18F]FBBG and [18F]pFBG while the biodistribution of [18F]mFBG was characterized in naïve animals. The results were validated by ex vivo biodistribution studies and immunofluorescence staining of the xenografts. All three radiotracers were produced in high radiochemical purity, molar activity and good yields. Western blot analysis revealed successful SNAPTag expression by the transfected HEK293 cells. In vitro testing revealed high target affinity of all three tracers with an up to 191-fold higher signal in the HEK293-SNAPTag cells compared to untransfected cells. This was further supported by a prominent radioactive protein band at the expected size in the SDS-PAGE autoradiograph of cells incubated with [18F]FBBG or [18F]pFBG. The in vivo studies demonstrated high uptake in HEK293-SNAP xenografts compared to HEK293 xenografts with excellent tumor-to-muscle ratios (7.5 ± 4.2 for [18F]FBBG and 10.6 ± 6.2 for [18F]pFBG). In contrast to [18F]pFBG and its chemical analogue [18F]mFBG, [18F]FBBG showed no signs of unspecific bone uptake and defluorination in vivo. Radiolabeled SNAPTag ligands bear great potential for clinical applications such as in vivo tracking of cell populations, antibody fragments and targeted radiotherapy. With excellent target affinity, good stability, and low non-specific binding, [18F]FBBG is a highly promising candidate for further preclinical evaluation.

31 March 2025 in Nuclear Medicine and Biology
Verified
Journal Article
Open access
VPVerena Pichler
Verena Pichler
MHMatthias Manfred Herth
Matthias Manfred Herth
VHVerena Hugenberg
Verena Hugenberg
PSPeter J.H. Scott
Peter J.H. Scott
SSSarah Spreckelmeyer
Sarah Spreckelmeyer
GPGiancarlo Pascali
Giancarlo Pascali
The rapid growth of radiopharmaceutical sciences, driven by regulatory approvals of theranostic agents and the expanding role of PET imaging, underscores the need for sustainable and green practices. While radiopharmaceuticals offer high precision and targeted therapy with minimal systemic toxicity, the field faces challenges related to increasing demand, energy consumption, and waste management. The nuclear medicine market is projected to reach $30 billion by 2030, necessitating the integration of sustainability principles such as green chemistry and green engineering into radiopharmaceutical development. Given the energy-intensive nature of radiochemical processes, these principles provide strategies for reducing environmental impact. However, radiopharmaceutical sciences require adaptations to traditional sustainability frameworks due to factors like radiation safety, speed, and automation. This perspective examines the applicability of the 12 principles of green chemistry and engineering, proposing nine key principles tailored to radiopharmaceutical sciences. These principles address waste prevention, radionuclide recycling, energy efficiency, and the adoption of cleaner irradiation technologies. As the field evolves, incorporating sustainability into training programs and research initiatives will be essential.

1 June 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
Sophie StotzSophie Stotz
Sophie Stotz
DBDaniel Bleher
Daniel Bleher
HKHubert Kalbacher
Hubert Kalbacher
AMAndreas Maurer
Andreas Maurer